All Regulatory Rapporteur articles in March 2023

View all stories from this issue.

  • Journal

    March 2023 – Contents

    March 2023   |   Volume 20   |   No.3

  • Direct healthcare professional communication as an intervention tool – retrospective analysis
    Journal

    Direct healthcare professional communication as an intervention tool – retrospective analysis

    2023-03-07T15:44:00Z

    The direct healthcare professional communication (DHPC) is a communication intervention by which important safety information is delivered directly to individual healthcare professionals (HCPs), alerting them to take certain actions to ensure the safe and effective use of medicines.

  • Setting the right standards
    Editorial

    Setting the right standards

    2023-03-07T13:39:00Z

    The theme of this issue is global standards but – as the contents reflect – the process by which documents and data become ‘standardised’ is anything but homogeneous or harmonised.

  • Is consulting in regulatory affairs your next career path?
    Journal

    Is consulting in regulatory affairs your next career path?

    2023-03-07T13:38:00Z

    Navigating the corporate ladder isn’t always clear cut. Along the way you may move in and out of the industry, stay in one position for too long, or even jump from specialist to director. Some ditch the politics all together and become their own boss. What is it like being a consultant, contingent worker, or contractor?

  • EMA’s IDMP-SPOR Implementation Guideline v2.1.1
    Journal

    EMA’s IDMP-SPOR Implementation Guideline v2.1.1

    2023-03-07T13:36:00Z

    Identification of Medicinal Products (IDMP) standards were developed by the ISO to specify the use of standardised definitions for the identification and description of medicinal products for human use. In this article, we provide an overview of the latest IDMP v2.1.1 guideline and summarise that, given the scope of changes, it is relatively low impact to the regulatory profession.

  • Environmental impact of pharmaceuticals and regulation in the EU
    Journal

    Environmental impact of pharmaceuticals and regulation in the EU

    2023-03-07T13:32:00Z

    The profound impact of pharmaceuticals on the environment has been acknowledged for decades. In the EU, two key mechanisms that assess this risk are the Environmental Risk Assessment (ERA), and Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). As both frameworks are under assessment, this article looks at the key considerations within the ERA.

  • IMDRF: Origins, purpose and current work
    Journal

    IMDRF: Origins, purpose and current work

    2023-03-07T13:29:00Z

    In a landscape of rapidly evolving technologies, the International Medical Device Regulatory Forum (IMDRF) aims to accelerate international medical device harmonisation. A summary of the work being undertaken by the IMDRF.

  • Understanding the key components of a clinical evaluation
    Case Study

    Understanding key components of a clinical evaluation

    Written by Angela Siebeneck, Director of Regulatory Strategy and Policy from Certara based on an online seminar presentation, made in collaboration with TOPRA and Certera, given on 15 November 2022.